Menu
X
image

Clinical Trials

If interested in volunteering to participate in a clinical research trial, or if you have concerns about the conduct of clinical research, please contact the Clinical Research office at (225) 215-1353, or by email at clinicalresearch@marybird.com.

ABOUT CLINICAL TRIALS

Research is key to the future of cancer care. Clinical trials enhance standard cancer treatments, resulting in improved patient outcomes and survival rates.

Through a National Cancer Institute Community Oncology Research Program (NCORP) grant presented to LSU Health Sciences Centers in New Orleans and Shreveport, in collaboration with Mary Bird Perkins Cancer Center, more advanced clinical trials will be offered to patients statewide. This effort is expected to reach about 80 percent of Louisiana residents, particularly minority populations, providing patients access to high-quality research studies closer to home.

Mary Bird Perkins Cancer Center sponsors clinical trials to seek the safest and most effective treatments for each cancer type. If you are considering participating in one of our clinical trials, you will receive a thorough explanation from your doctor with all the information you need to make an informed decision. Our physicians offer many clinical trials at any given time, including brain, breast, colorectal, head and neck, kidney, lung, melanoma, pancreas and prostate studies.

WHAT IS A CLINICAL TRIAL?
Clinical trials are research studies that involve human beings in order to test new ways to prevent, detect, diagnose or treat diseases. A drug must be part of a clinical trial before the FDA will approve it to be put on the market.

WHAT IS THE PURPOSE OF ONCOLOGY CLINICAL TRIALS?
Oncology clinical trials are conducted in order to test new drugs or a new combination of drug treatments, new surgery and radiation therapies and new medical devices.

HOW DO I JOIN A TRIAL?
There are three ways you can sign up for a clinical trial:

  1. Physician Referral: Ask your doctor about participating in one of our trials.
  2. Phone: Call our clinical research department
    • Baton Rouge, Gonzales, Hammond – (225) 215-1353
    • Covington – (985) 276-6843
    • Houma – (985) 850-6300
  3. Email: Contact our clinical research department at clinicalresearch@marybird.com.
BLADDER/UROTHELIAL

Title:  A Prospective Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery for Patients with High Grade Upper Tract Urothelial Carcinoma

Purpose:  This phase II trial studies how well giving chemotherapy before surgery works in treating patients with aggressive upper urinary tract cancer. Drugs used in chemotherapy, such as methotrexate, vinblastine, doxorubicin hydrochloride, cisplatin, gemcitabine hydrochloride, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Removing the affected upper urinary tract by surgery is the recommended treatment for upper urinary tract cancer, but can cause loss of kidney function and prevent patients from being able to receive chemotherapy after surgery. Giving chemotherapy before surgery, when the kidneys are working at their maximum, may allow less tissue to be removed during surgery and may be more effective in treating patients with high grade upper urinary tract cancer.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble,  Naveed Khan, and Harry McGaw .

Offered in:  Baton Rouge, Covington, Houma

Title:  A Randomized Phase II Study of CO-eXpression ExtrapolatioN (COXEN) with Neoadjuvant Chemotherapy for Localized, Muscle-Invasive Bladder Cancer

Purpose:  The primary focus of this study is to see if looking at tumor biomarkers using a program called coexpression extrapolation or “COXEN” may predict a patient’s response to chemotherapy before surgery.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert GambleNaveed Khan, and Harry McGaw .

Offered in:  Baton Rouge, Covington, Houma

BREAST

Title:  A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Purpose:  Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble, Naveed Khan, and Harry McGaw

Offered in:  Baton Rouge, Covington, Houma

Title: A Randomized Phase III Trial of Endocrine Therapy Plus Entinostat/Placebo in Patients with Hormone Receptor-Positive Advanced Breast Cancer

Purpose: This randomized phase III trial studies exemestane and entinostat to see how well they work compared to exemestane alone in treating patients with hormone receptor-positive breast cancer that has spread to nearby tissue or lymph nodes or another place in the body. Estrogen can cause the growth of breast cancer cells. Endocrine therapy using exemestane may fight breast cancer by lowering the amount of estrogen the body makes. Entinostat may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether exemestane is more effective with or without entinostat in treating breast cancer.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph ShowsDerrick SpellSiva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble, Naveed Khan, and Harry McGaw.

Offered in: Baton Rouge, Covington, Houma

Title:  A Randomized, Double-Blind, Parallel Group, Placebo-Controlled Multi-Centre Phase III Study to Assess the Efficacy and Safety of Olaparib Versus Placebo as Adjuvant Treatment in Patients with Germline BRCA1/2 Mutations and High Risk HER2 Negative Primary Breast Cancer Who Have Completed Definitive Local Treatment and Neoadjuvant or Adjuvant Chemotherapy

Purpose:  Olaparib treatment in patients with germline BRCA1/2 mutations and high risk HER2 negative primary breast cancer who have completed definitive local treatment and neoadjuvant or adjuvant chemotherapy.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; Robert Gamble, Naveed Khan, and Harry McGaw; James Carinder, Carrie Marquette, and Jack Saux.

Offered in:  Baton Rouge, Covington, Houma

Title: A Randomized Phase III Trial of Adjuvant Therapy Comparing Doxorubicin Plus Cyclophosphamide Followed by Weekly Paclitaxel with or Without Carboplatin for Node-Positive or High-Risk Node-Negative Triple-Negative Invasive Breast Cancer

Purpose: This randomized phase III trial studies how well doxorubicin hydrochloride and cyclophosphamide followed by paclitaxel with or without carboplatin work in treating patients with triple-negative breast cancer. Drugs used in chemotherapy, such as doxorubicin hydrochloride, cyclophosphamide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether doxorubicin hydrochloride and cyclophosphamide is more effective when followed by paclitaxel alone or paclitaxel and carboplatin in treating triple-negative breast cancer.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince CataldoDavid Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; Robert Gamble, Naveed Khan, and Harry McGaw; James Carinder, Carrie Marquette, and Jack Saux.

Offered in: Baton Rouge, Covington, Houma

Title:  A Randomized Phase III Clinical Trial Evaluating Post-Mastectomy Chestwall and Regional Nodal XRT and Post-Lumpectomy Regional Nodal XRT in Patients with Positive Axillary Nodes Before Neoadjuvant Chemotherapy Who Convert to Pathologically Negative Axillary Nodes After Neoadjuvant Chemotherapy

Purpose:  This randomized phase III trial studies standard or comprehensive radiation therapy in treating patients with early-stage breast cancer who have undergone surgery. Radiation therapy uses high-energy x rays to kill tumor cells. It is not yet known whether comprehensive radiation therapy is more effective than standard radiation therapy in treating patients with breast cancer.

Physicians:  Katherine Castle, Robert Fields, Maurice King, Renee Levine, Jingya Wang and Charles Wood; Andrew Elson;  Jeffrey Long.

Offered in:  Baton Rouge, Covington, Gonzales, Hammond and Houma

Title: Randomized Phase III Trial Evaluating the Role of Weight Loss in Adjuvant Treatment of Overweight and Obese Women with Early Breast Cancer (BWEL Study)

Purpose: This randomized phase III trial studies whether weight loss in overweight and obese women may prevent breast cancer from coming back (recurrence). Previous studies have found that women who are overweight or obese when their breast cancer is found (diagnosed) have a greater risk of their breast cancer recurring, as compared to women who were thinner when their cancer was diagnosed. This study aims to test whether overweight or obese women who take part in a weight loss program after being diagnosed with breast cancer have a lower rate of cancer recurrence as compared to women who do not take part in the weight loss program. This study will help to show whether weight loss programs should be a part of breast cancer treatment.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, Robert Fields, David Hanson, Maurice King, Renee LevineKellie Schmeeckle, Joseph Shows, Derrick Spell, Jingya Wang, Charles Wood, Siva Yadlapati and Lauren Zatarain;  James Carinder, Andrew Elson, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan, Jeffrey Long and Harry McGaw.

Offered in: Baton Rouge, Covington, Houma

Title:  A Randomized Phase III Double Blinded Placebo Controlled Trial of Aspirin as Adjuvant Therapy for Node Positive HER2 Negative Breast Cancer: The ABC Trial

Purpose: This randomized phase III trial studies how well aspirin works in preventing the cancer from coming back (recurrence) in patients with human epidermal growth factor receptor 2 (HER2) breast cancer after chemotherapy, surgery, and/or radiation therapy. Aspirin is a drug that reduces pain, fever, inflammation, and blood clotting. It is also being studied in cancer prevention. Giving aspirin may reduce the rate of cancer recurrence in patients with breast cancer.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain;  James Carinder, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan and Harry McGaw.

Offered in: Baton Rouge, Covington, Houma

Title:  A Randomized Phase III Post-Operative Trial of Platinum Based Chemotherapy Vs. Observation in Patients with Residual Triple-Negative Basal-Like Breast Cancer Following Neoadjuvant Chemotherapy

Purpose: This randomized phase III trial studies how well cisplatin or carboplatin (platinum based chemotherapy) works compared to capecitabine in treating patients with remaining (residual) basal-like triple-negative breast cancer following chemotherapy after surgery (neoadjuvant). Drugs used in chemotherapy, such as cisplatin, carboplatin and capecitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether cisplatin or carboplatin is more effective than capecitabine in treating patients with residual triple negative basal-like breast cancer.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain;  James Carinder, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan and Harry McGaw.

Offered in: Baton Rouge, Covington, Houma

CARCINOID

There are currently no active carcinoid clinical trials. Please check back as we are continuously opening new studies.

COLORECTAL

Title: A Randomized Phase II Study of Irinotecan and Cetuximab with or Without the Anti-Angiogenic Antibody, Ramucirumab (IMC-1121B), in Advanced, K-ras Wild-Type Colorectal Cancer Following Progression on Bevacizumab-Containing Chemotherapy

Purpose: Drugs used in chemotherapy, such as irinotecan hydrochloride, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Monoclonal antibodies, such as cetuximab and ramucirumab, can block tumor growth in different ways. Some block the ability of tumor cells to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Cetuximab and ramucirumab may also stop the growth of colorectal cancer by blocking blood flow to the tumor. It is not yet know whether giving cetuximab and irinotecan hydrochloride together is more effective with or without ramucirumab in treating colorectal cancer.  This randomized phase II trial is studying the side effects and how well giving cetuximab and irinotecan hydrochloride with or without ramucirumab work in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince CataldoDavid Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan and Harry McGaw

Offered in: Baton Rouge, Covington, Houma

Title: A Single Arm, Open-Label, Multicenter, Multinational,Safety and Efficacy Phase IIIB Trial of BI695502 in Patients with Previously Untreated Metastatic Colorectal Cancer

Purpose: This randomized phase II trial is studying the side effects and how well giving cetuximab and irinotecan hydrochloride with or without ramucirumab work in treating patients with advanced colorectal cancer with progressive disease after treatment with bevacizumab-containing chemotherapy.

Physicians: Drs. Deborah AbernathyDavid Hanson, Kellie Schmeeckle and Derrick Spell

Offered in: Baton Rouge

Click Here for More Information

ESOPHAGEAL

There are currently no active esophageal clinical trials. Please check back as we are continuously opening new studies.

GASTRIC

There are currently no active gastric clinical trials. Please check back as we are continuously opening new studies.

GYNECOLOGY

There are currently no active gynecology clinical trials. Please check back as we are continuously opening new studies.

HEAD & NECK

There are currently no active head and neck clinical trials. Please check back as we are continuously opening new studies.

LIVER

There are currently no active liver clinical trials. Please check back as we are continuously opening new studies.

LUNG

Title: Adjuvant Lung Cancer Enrichment Marker Identification and Sequencing Trial (ALCHEMIST)

Purpose: This research trial studies genetic testing in screening patients with stage IB-IIIA non-small cell lung cancer that has been or will be removed by surgery. Studying the genes in a patient’s tumor cells may help doctors select the best treatment for patients that have certain genetic changes.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick SpellSiva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble, Naveed Khan and Harry Mcgaw.

Offered in: Baton Rouge, Covington, and Houma.

Title: Randomized Double Blind Placebo Controlled Study of Erlotinib or Placebo in Patients with Completely Resected Epidermal Growth Factor Receptor (EGFR) Mutant Non-Small Cell Lung Cancer (NSCLC)

Purpose: This randomized phase III trial studies how well erlotinib hydrochloride compared to placebo works in treating patients with stage IB-IIIA non-small cell lung cancer that has been completely removed by surgery. Erlotinib hydrochloride may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince CataldoDavid Hanson, Kellie Schmeeckle, Joseph Shows, Derrick SpellSiva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble, Naveed Khan and Harry McGaw 

Offered in: Baton Rouge, Covington, and Houma.

Title: A Phase III Double-Blind Trial for Surgically Resected Early Stage Non-Small Cell Lung Cancer: Crizotinib Versus Placebo for Patients with Tumors Harboring the Anaplastic Lymphoma Kinase (ALK) Fusion Protein

Purpose: This randomized phase III trial studies how well crizotinib works and compares it to placebo in treating patients with stage IB-IIIA non-small cell lung cancer that has been removed by surgery and has a mutation in a protein called anaplastic lymphoma kinase (ALK). Mutations, or changes, in ALK can make it very active and important for tumor cell growth and progression. Crizotinib may stop the growth of tumor cells by blocking the ALK protein from working. Crizotinib may be an effective treatment for patients with non-small cell lung cancer and an ALK fusion mutation.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain;  James Carinder, Carrie Marquette and Jack Saux; Robert GambleNaveed Khan and Harry McGaw

Offered in: Baton Rouge, Covington, and Houma.

Title: A Biomarker-Driven Master Protocol for Previously Treated Squamous Cell Lung Cancer (Lung-Map)

Purpose: This screening and multi-sub-study randomized phase II/III trial will establish a method for genomic screening of similar large cancer populations followed by assigning and accruing simultaneously to a multi-sub-study hybrid “Master Protocol” (S1400). The type of cancer trait (biomarker) will determine to which sub-study, within this protocol, a participant will be assigned to compare new targeted cancer therapy, designed to block the growth and spread of cancer, or combinations to standard of care therapy with the ultimate goal of being able to approve new targeted therapies in this setting. In addition, the protocol includes a “non-match” sub-study which will include all screened patients not eligible for any of the biomarker-driven sub-studies. This sub-study will compare a non-match therapy to standard of care also with the goal of approval.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph ShowsDerrick SpellSiva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan and Harry McGaw

Offered in: Baton Rouge, Covington, Houma

Title: Adjuvant Nivolumab in Resected Lung Cancers (ANVIL)-A Randomized Phase III Study of Nivolumab After Surgical Resection and Adjuvant Chemotherapy in Non-Small Cell Lung Cancers

Purpose: This randomized phase III trial studies how well nivolumab after surgery and chemotherapy work in treating patients with stage IB-IIIA non-small cell lung cancer. Monoclonal antibodies, such as nivolumab, may stimulate the immune system in different ways and kill tumor cells remaining after surgery and standard of care chemotherapy.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain;  James Carinder, Carrie Marquette and Jack Saux; Robert GambleNaveed Khan and Harry McGaw

Offered in: Baton Rouge, Covington, and Houma.

Title: A Dose Frequency Optimization,Trial of Nivolumab 240 mg Every 2 Weeks vs Nivolumab 480 mg Every 4 Weeks in Subjects With Advanced or Metastatic Non-small Cell Lung Cancer Who Received Up to 12 Months of Nivolumab at 3 mg/kg or 240 mg Every 2 Weeks

Purpose: The primary objective of this study is to show that PFS (progress-free survival) rate at 6 months and at 1 year after randomization, of Nivolumab 480 mg every 4 weeks is non-inferior to nivolumab 240 mg every 2 weeks in subjects with advanced/metastatic (Stage IIIb/IV) NSCLC (non-Sq and Sq).

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain

Offered in: Baton Rouge

Title: A Study to Evaluate a Panel of Biomarkers for Use in Patients Undergoing Evaluation for Lung Cancer

Purpose: The purpose of this study is to evaluate if an experimental blood test, known as the ONC-LN-04 Lung Test, for the detection of lung cancer. The patient is being asked to be in this study because they have an upcoming screening or have scheduled a lung biopsy and may meet the study requirements.

Physicians: Drs. Brad Vincent; Andrew Elson; Naveed Khan

Offered in: Baton Rouge, Covington, and Houma.

Title: Phase III Comparison of Thoracic Radiotherapy Regimens in Patients with Limited Small Cell Lung Cancer Also Receiving Cisplatin or Carboplatin and Etoposide

Purpose: Radiation therapy uses high-energy x-rays to kill tumor cells. Drugs used in chemotherapy, such as etoposide, carboplatin and cisplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. It is not yet known which radiation therapy regimen is more effective when given together with chemotherapy in treating patients with limited-stage small cell lung cancer. This randomized phase III trial is comparing different chest radiation therapy regimens to see how well they work in treating patients with limited-stage small cell lung cancer.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain;  James Carinder, Carrie Marquette and Jack Saux; Robert GambleNaveed Khan and Harry McGaw

Offered in: Baton Rouge, Covington, and Houma.

LYMPHOMA

There are currently no active lymphoma clinical trials. Please check back as we are continuously opening new studies.

MELANOMA

There are currently no active melanoma clinical trials. Please check back as we are continuously opening new studies.

MULTI SITE/MULTI DISEASE

Title: A Sero-Epidemiologic Survey and Cost-Effectiveness Study of Screening for Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV) and Hepatitis C Virus (HCV) Among Newly Diagnosed Cancer Patients

Purpose: The goal of this study is to estimate the prevalence of HIV, Hepatitis B and hepatitis C infection among newly diagnosed cancer patients presenting to community and academic oncology clinics.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Katherine Castle, Vince Cataldo, Robert Fields, David Hanson, Maurice King, Renee LevineKellie Schmeeckle, Joseph Shows, Derrick Spell, Jingya Wang, Charles Wood, Siva Yadlapati and Lauren Zatarain; Patricia Braly, James Carinder, Andrew Elson, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan, Jeffrey Long and Harry McGaw.

Offered in: Baton Rouge, Covington, Houma

Title: Molecular Analysis for Therapy Choice (MATCH)

Purpose: This phase II trial studies how well treatment that is directed by genetic testing works in patients with solid tumors or lymphomas that have progressed following at least one line of standard treatment or for which no agreed upon treatment approach exists. Genetic tests look at the unique genetic material (genes) of patients’ tumor cells. Patients with genetic abnormalities (such as mutations, amplifications, or translocations) may benefit more from treatment which targets their tumor’s particular genetic abnormality. Identifying these genetic abnormalities first may help doctors plan better treatment for patients with solid tumors, lymphomas, or multiple myeloma.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Katherine Castle, Vince Cataldo, Robert Fields, David Hanson, Maurice King, Renee LevineKellie Schmeeckle, Joseph Shows, Derrick Spell, Jingya Wang, Charles Wood, Siva Yadlapati and Lauren Zatarain; Patricia Braly, James Carinder, Andrew Elson, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan, Jeffrey Long and Harry McGaw.

Offered in: Baton Rouge, Covington, Houma

MULTIPLE MYELOMA

Title:  Randomized Phase III Trial of Bortezomib, Lenalidomide and Dexamethasone versus Carfilzomib, Lenalidomide Dexamethasone Followed by Limited or Indefinite Duration Lenalidomide Maintenance in Patients with Newly Diagnosed Symptomatic Multiple Myeloma

Purpose: This randomized phase III trial studies bortezomib, lenalidomide, and dexamethasone to see how well it works compared to carfilzomib, lenalidomide, and dexamethasone in treating patients with newly diagnosed multiple myeloma. Bortezomib and carfilzomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. Drugs used in chemotherapy, such as lenalidomide and dexamethasone, work in different ways to stop the growth of cancer cells, either by killing the cells or by stopping them from dividing. Giving bortezomib or carfilzomib together with lenalidomide and dexamethasone may kill more cancer cells.

Physicians: Drs. Deborah Abernathy, Bryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle,  Joseph Shows, Derrick Spell, Siva Yadlapati, and Lauren Zatarain; James Carinder, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan, and Harry McGaw.

Offered in:  Baton Rouge, Covington, Houma

NEURO

There are currently no active neuro clinical trials. Please check back as we are continuously opening new studies.

OBSERVATIONAL TRIALS

Title: The Myelodysplastic Syndromes (MDS) and Acute Myeloid Leukemia (AML) Disease Registry.

Purpose: The purpose of this study is to use the information collected to help better understand patterns for diagnosis, treatment and outcomes, including disease progression. In addition, information is being collected to help better understand patterns for the quality of life in patients newly diagnosed with Lower-Risk, Higher-Risk, or unknown risk MDS or AML. The final reason is to use the results of this study to provide information to help better understand the effect different treatments have on a patient’s disease and on their quality of life.

Physicians: Bryan Bienvenu, David Hanson, Kellie Schmeeckle and Derrick Spell

Offered in: Baton Rouge

Title:  A Prospective Observational Cohort Study of Patients with Castration Resistant Prostate Cancer (CRPC) in the United States.  (CRPC Registry)

Purpose:  The reason this registry is being set up is to describe patterns of care, disease assessment methods, treatment decisions, treatment settings, physician referral patterns and to find out how the patients’ CRPC symptoms have improved while on their CRPC therapy.

Physicians: David Hanson, Bryan Bienvenu, Kellie Schmeeckle, Derrick SpellHarry McGaw, Robert Gamble and Naveed Khan.

Offered in:  Baton Rouge and Houma

Title:  A Study to Evaluate a Panel of Biomarkers for Use in Patients Undergoing Evaluation for Lung Cancer, ONC-LN-04.

Purpose:  The purpose of this study is to evaluate if an experimental blood test, known as the ONC-LN-04 Lung Test, for the detection of lung cancer. The patient is being asked to be in this study because they have an upcoming screening or have scheduled a lung biopsy and may meet the study requirements.

Physicians:  Brad Vincent; Andrew Elson; and Naveed Khan.

Offered in:  Baton Rouge, Covington and Houma

OVARIAN

There are currently no active ovarian clinical trials. Please check back as we are continuously opening new studies.

PANCREATIC

Title: Study of Ibrutinib vs Placebo, in Combination with Nab-paclitaxel and Gemcitabine, in the First Line Treatment of Patients With Metastatic Pancreatic Adenocarcinoma (RESOLVE)

Purpose:  This is a phase 2/3 to evaluate the efficacy of ibrutinib in combination with nab-paclitaxel and gemcitabine for the first line treatment of patients with metastatic pancreatic adenocarcinoma.

Physician(s): Drs. Deborah Abernathy, Bryan Bienvenu, Vince CataldoDavid HansonKellie Schmeeckle, Joseph Shows, Derrick SpellSiva Yadlapati and Lauren Zatarain.

Offered in:  Baton Rouge

PREVENTION

There are currently no active prevention clinical trials. Please check back as we are continuously opening new studies.

PROSTATE

Title:  Observational Cohort Study of Patients with Castration-Resistant Prostate Cancer (CRPC) (TRUMPET)

Purpose:  The purpose of this study is to describe patterns of care in CRPC patients, as well as health-related quality of life (HRQoL) outcomes associated with CRPC and its management.

Physicians: Drs. Bryan Bienvenu, David Hanson, Kellie Schmeeckle and Derrick Spell; Robert Gamble, Naveed Khan and Harry McGaw.

Offered in:  Baton Rouge, Houma

Title:  Androgen Deprivation Therapy and High Dose Radiotherapy with or Without Whole-Pelvic Radiotherapy in Unfavorable Intermediate or Favorable High Risk Prostate Cancer: A Phase III Randomized Trial

Purpose:  This study will also describe factors influencing treatment decisions including reason(s) for treatment choices and triggers for treatment changes for CRPC as well as describe clinical outcomes based on patient characteristics.

Physicians: Drs. Katherine Castle, Robert Fields, Maurice King, Renee Levine, Jingya Wang and Charles Wood; Andrew Elson; Jeffrey Long

Offered in:  Baton Rouge, Covington, Houma

RENAL

There are currently no active renal clinical trials. Please check back as we are continuously opening new studies

SKIN

Title:  A Randomized Phase II Trial of Ipilimumab with or Without Bevacizumab in Patients with Unresectable Stage III or Stage IV Melanoma

Purpose:  This randomized phase II trial studies how well ipilimumab with or without bevacizumab works in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and bevacizumab, block tumor growth in different ways by targeting certain cells.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble, Naveed Khan, and Harry McGaw

Offered in:  Baton Rouge, Covington, Houma

Title:  A Randomized Phase III Trial of Dabrafenib + Trametinib Followed by Ipilimumab + Nivolumab at Progression vs. Ipilimumab + Nivolumab Followed by Dabrafenib + Trametinib at Progression in Patients with Advanced BRAFV600 Mutant Melanoma

Purpose:  This randomized phase III trial studies how well initial treatment with ipilimumab and nivolumab followed by dabrafenib and trametinib works and compares it to initial treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab in treating patients with stage III-IV melanoma that contains a mutation known as BRAFV600 and cannot be removed by surgery. Ipilimumab and nivolumab may block tumor growth by targeting certain cells. Dabrafenib and trametinib may block tumor growth by targeting the BRAFV600 gene. It is not yet known whether treating patients with ipilimumab and nivolumab followed by dabrafenib and trametinib is more effective than treatment with dabrafenib and trametinib followed by ipilimumab and nivolumab.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble, Naveed Khan, and Harry McGaw

Offered in:  Baton Rouge, Covington, Houma

Title:  Randomized Phase II/III Study of Nivolumab Plus Ipilimumab Plus Sargramostim Versus Nivolumab Plus Ipilimumab in Patients with Unresectable Stage III or Stage IV Melanoma

Purpose:  This randomized phase II/III trial studies the side effects and best dose of nivolumab and ipilimumab when given together with or without sargramostim and to see how well they work in treating patients with stage III-IV melanoma that cannot be removed by surgery. Monoclonal antibodies, such as ipilimumab and nivolumab, may kill tumor cells by blocking blood flow to the tumor, by stimulating white blood cells to kill the tumor cells, or by attacking specific tumor cells and stop them from growing or kill them. Colony-stimulating factors, such as sargramostim, may increase the production of white blood cells. It is not yet known whether nivolumab and ipilimumab are more effective with or without sargramostim in treating patients with melanoma.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette, and Jack Saux; Robert Gamble, Naveed Khan, and Harry McGaw

Offered in:  Baton Rouge, Covington, Houma

Title:  A Phase III Randomized Trial Comparing Physician/Patient Choice of Either High Dose Interferon or Ipilimumab to MK-3475 (Pembrolizumab) in Patients with High Risk Resected Melanoma

Purpose:  This randomized phase III trial studies how well high-dose recombinant interferon alfa-2B or ipilimumab works compared with pembrolizumab in treating patients with stage III-IV melanoma that has been removed by surgery but is likely to come back or spread. High-dose recombinant interferon alfa-2B may help shrink or slow the growth of melanoma. Monoclonal antibodies, such as ipilimumab and pembrolizumab, may block tumor growth in different ways by targeting certain cells. It is not yet known whether high-dose recombinant interferon alfa-2B or ipilimumab is more effective than pembrolizumab in treating patients with melanoma.

Physicians: Drs. Deborah AbernathyBryan Bienvenu, Vince Cataldo, David Hanson, Kellie Schmeeckle, Joseph Shows, Derrick Spell, Siva Yadlapati and Lauren Zatarain; James Carinder, Carrie Marquette and Jack Saux; Robert Gamble, Naveed Khan, and Harry McGaw

Offered in:  Baton Rouge, Covington, Houma

ABOUT NCORP

Louisiana and Gulf South residents have more options for advanced cancer treatment, thanks to a $5.6 million National Cancer Institute Community Oncology Research Program (NCORP) award. The NCORP grant continues through 2019 and focuses on conducting multi-site cancer clinical trials and cancer care delivery research studies in many Louisiana communities.

The Cancer Center is collaborating with LSU Health Sciences Center-New Orleans and LSU Health Sciences Center-Shreveport, referred to collectively as the Gulf South Minority/Underserved  NCI Community Oncology Research Program (GS-MU-NCORP), to combine our strengths and experiences and bring more state-of-the-art NCI clinical trials to Louisiana cancer patients. Through this effort, we will reach about 80 percent of the state, including the most rural and urban areas where there are often great disparities in cancer care.

This grant expands cancer prevention, screening and survivorship clinical trials to improve early diagnosis and treatment as well as help patients cope with the extended process of getting back to their pre-cancer lives. Additionally, the initiative includes a multidisciplinary approach to patient care to provide the most comprehensive treatment plan for patients.

 

LEARN MORE:

© Copyright 2017 Mary Bird Perkins Cancer Center. All rights reserved.